Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Alimera Sciences Inc ALIM

Healthcare
Alimera Sciences, Inc. is a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic retinal pharmaceuticals. It is engaged in developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a cause of blindness, and outside the United States for non-infectious uveitis affecting the posterior segment of the eye ... see more

Recent & Breaking News (NDAQ:ALIM)

Alimera Sciences Reports Second Quarter 2017 Financial Results

GlobeNewswire August 2, 2017

Alimera Sciences Announces Real-World Audit Data Supporting the Positive Benefits of ILUVIEN® Treatment

GlobeNewswire July 25, 2017

Alimera Sciences to Report Second Quarter 2017 Financial Results on August 2nd, 2017

GlobeNewswire July 24, 2017

Positive Results Enable Alimera Sciences to Reduce Enrollment in ILUVIEN® Registry Safety Study in the U.K.

GlobeNewswire July 19, 2017

Alimera Sciences Announces Italian Patients Now Being Treated With ILUVIEN®

GlobeNewswire July 12, 2017

Alimera Sciences To Expand ILUVIEN® Indication in Europe for Posterior Uveitis

GlobeNewswire July 10, 2017

pSivida Out-licenses EMEA Rights for Durasert™ Three-year Treatment for Posterior Segment Uveitis While Retaining U.S. Commercial Rights; Amended Global Collaboration Agreement with Alimera for ILUVIEN® Improves pSivida’s Revenue Generation

GlobeNewswire July 10, 2017

Research Reports Initiation on Drug Makers Stocks -- Immune Pharma, Impax Labs, Heron Therapeutics, and Alimera Sciences

PR Newswire June 2, 2017

Investor Network: ALIMERA SCIENCES INC to Host Earnings Call

Accesswire May 9, 2017

Alimera Sciences Reports First Quarter 2017 Financial Results

GlobeNewswire May 8, 2017

Alimera Sciences to Report First Quarter 2017 Financial Results on May 8th, 2017

GlobeNewswire May 3, 2017

Alimera Sciences Announces Data From 27 ILUVIEN® Studies to Be Presented at 2017 ARVO

GlobeNewswire May 1, 2017

Alimera's Commercial Steroid Implant For Diabetic Macular Edema, Explored

Benzinga.com  April 30, 2017

Alimera Sciences Signs Agreement for Exclusive Distributor of ILUVIEN® in Spain

GlobeNewswire March 13, 2017

Alimera Sciences to Present at the 29th Annual ROTH Conference

GlobeNewswire March 7, 2017

Alimera Sciences to Present at the 37th Annual Cowen Health Care Conference

GlobeNewswire March 3, 2017

Alimera Sciences Reports Record Fourth Quarter and Full Year 2016 Financial Results

GlobeNewswire March 1, 2017

Alimera Sciences to Report Fourth Quarter 2016 Financial Results on March 1, 2017

GlobeNewswire February 23, 2017

Alimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien(R) in Canada

MarketWire Canada February 22, 2017

Alimera Sciences and Knight Therapeutics Announce Filing of New Drug Submission for Iluvien® in Canada

GlobeNewswire February 22, 2017